PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages

  • Authors:
    • Zhihan Tang
    • Lu Jiang
    • Juan Peng
    • Zhong Ren
    • Dangheng Wei
    • Chunyang Wu
    • Lihong Pan
    • Zhisheng Jiang
    • Lushan Liu
  • View Affiliations

  • Published online on: July 20, 2012     https://doi.org/10.3892/ijmm.2012.1072
  • Pages: 931-938
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Proprotein convertase subtilisin/kexin 9 (PCSK9), a member of the protein-converting enzyme family, is highly expressed in adult hepatocytes and small intestinal enterocytes. To our knowledge, in this study, we demonstrate for the first time that PCSK9 is upregulated in a dose-dependent manner via oxidized low-density lipoprotein (oxLDL) stimulation in THP-1-derived macrophages. PCSK9 small interfering RNA (siRNA) suppresses the oxLDL-induced inflammatory cytokine expression in THP-1-derived macrophages. The exposure of macrophages to oxLDL markedly increased the expression of NF-κB protein in the nucleus. However, this effect was significantly attenuated by PCSK9 siRNA. These findings indicate that PCSK9 expression is induced by oxLDL, and that PCSK9 siRNA protects against inflammation via the inhibition of NF-κB activation in oxLDL-stimulated THP-1-derived macrophages. Our results suggest that PCSK9 may be used as a therapeutic target for the treatment of atherosclerosis since PCSK9 siRNA suppresses oxLDL-induced IκB-α degradation and NF-κB nuclear translocation into THP-1-derived macrophages.

References

1. 

B CariouC Le MayP CostetClinical aspects of PCSK9Atherosclerosis216258265201110.1016/j.atherosclerosis.2011.04.01821596380

2. 

KN MaxwellRE SoccioEM DuncanE SehayekJL BreslowNovel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed miceJ Lipid Res4421092119200310.1194/jlr.M300203-JLR20012897189

3. 

NG SeidahS BenjannetL WickhamThe secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiationProc Natl Acad Sci USA100928933200310.1073/pnas.0335507100

4. 

T YamamotoC LuRO RyanA two-step binding model of PCSK9 interaction with the low density lipoprotein receptorJ Biol Chem28654645470201110.1074/jbc.M110.19904221149300

5. 

J DavignonG DubucNG SeidahThe influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosisCurr Atheroscler Rep12308315201010.1007/s11883-010-0123-620623344

6. 

SA MousaviKE BergeTP LerenThe unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasisJ Intern Med266507519200910.1111/j.1365-2796.2009.02167.x19930098

7. 

AJ MarianPCSK9 as a therapeutic target in atherosclerosisCurr Atheroscler Rep12151154201010.1007/s11883-010-0099-220425252

8. 

CJ DuffNM HooperPCSK9: an emerging target for treatment of hypercholesterolemiaExpert Opin Ther Targets15157168201110.1517/14728222.2011.54748021204732

9. 

S PoirierA PratE MarcinkiewiczImplication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous systemJ Neurochem98838850200610.1111/j.1471-4159.2006.03928.x16893422

10. 

KR FeingoldAH MoserJK ShigenagaSM PatzekC GrunfeldInflammation stimulates the expression of PCSK9Biochem Biophys Res Commun374341344200810.1016/j.bbrc.2008.07.02318638454

11. 

H LanL PangMM SmithProprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cellsJ Cell Physiol224273281201020333646

12. 

R RossAtherosclerosis is an inflammatory diseaseAm Heart J138S419S420199910.1016/S0002-8703(99)70266-810539839

13. 

G RodriguezN MagoF RosaRole of inflammation in atherogenesisInvest Clin501091292009

14. 

P SahaB ModaraiJ HumphriesK MattockM WalthamKG BurnandA SmithThe monocyte/macrophage as a therapeutic target in atherosclerosisCurr Opin Pharmacol9109118200910.1016/j.coph.2008.12.01719230773

15. 

CY WuZH TangL JiangXF LiZS JiangLS LiuPCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathwayMol Cell Biochem359347358201210.1007/s11010-011-1028-621847580

16. 

ZH TangLS LiuJ PengQ YangHT LiuZS JiangInvestigation of NARC-1 protein expression in atherosclerotic lesion of New Zealand rabbitChin J Arterioscler1735372009(in Chinese)

17. 

P LibbyY OkamotoVZ RochaE FolcoInflammation in atherosclerosis: transition from theory to practiceCirc J74213220201020065609

18. 

K YinC TangInflammation, lipid metabolism dysfunction, and hypertension: Active research fields in atherosclerosis-related cardiovascular disease in ChinaSci China Life Sci54976979201110.1007/s11427-011-4225-3

19. 

KL MaXZ RuanSH PowisY ChenJF MoorheadZ VargheseInflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout miceHepatology48770781200810.1002/hep.2242318752326

20. 

K YinDF LiaoCK TangATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transportMol Med16438449201020485864

21. 

K YinX DengZC MoTristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A–I: role of ATP-binding membrane cassette transporter A1 and signal transducer and activator of transcription 3J Biol Chem2861383413845201121339300

22. 

A RoubtsovaMN MunkondaZ AwanCirculating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissueArterioscler Thromb Vasc Biol31785791201110.1161/ATVBAHA.110.220988

23. 

OL HollaJ CameronK TvetenTB StromKE BergeJK LaerdahlTP LerenRole of the C-terminal domain of PCSK9 in degradation of the LDL receptorsJ Lipid Res5217871794201110.1194/jlr.M01809321771976

24. 

AK SoutarUnexpected roles for PCSK9 in lipid metabolismCurr Opin Lipidol22192196201110.1097/MOL.0b013e32834622b521494143

25. 

TS FisherP Lo SurdoS PanditEffects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulationJ Biol Chem2822050220512200710.1074/jbc.M70163420017493938

26. 

D CunninghamDE DanleyKF GeogheganStructural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaNat Struct Mol Biol14413419200710.1038/nsmb123517435765

27. 

DW ZhangTA LagaceR GarutiZ ZhaoM McDonaldJD HortonJC CohenHH HobbsBinding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradationJ Biol Chem2821860218612200710.1074/jbc.M702027200

28. 

J CameronOL HollaT RanheimMA KulsethKE BergeTP LerenEffect of mutations in the PCSK9 gene on the cell surface LDL receptorsHum Mol Genet1515511558200610.1093/hmg/ddl07716571601

29. 

M MbikayF SiroisJ MaynePCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalitiesFEBS Lett584701706201010.1016/j.febslet.2009.12.01820026049

30. 

C LanghiC Le MayV GmyrPCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretionBiochem Biophys Res Commun39012881293200910.1016/j.bbrc.2009.10.13819878649

31. 

K De BosscherBW VandenG HaegemanThe interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repressionEndocr Rev244885222003

32. 

G GloireS Legrand-PoelsJ PietteNF-kappaB activation by reactive oxygen species: fifteen years laterBiochem Pharmacol7214931505200616723122

33. 

MP de WintherE KantersG KraalMH HofkerNuclear factor kappaB signaling in atherogenesisArterioscler Thromb Vasc Biol25904914200515731497

34. 

C XieJ KangME FergusonS NagarajanTM BadgerX WuBlueberries reduce pro-inflammatory cytokine TNF-α and IL-6 production in mouse macrophages by inhibiting NF-κB activation and the MAPK pathwayMol Nutr Food Res55158715912011

35. 

L LeiH LiF YanY LiY XiaoPorphyromonas gingivalis lipopolysaccharide alters atherosclerotic-related gene expression in oxidized low-density-lipoprotein-induced macrophages and foam cellsJ Periodontal Res46427437201110.1111/j.1600-0765.2011.01356.x

Related Articles

Journal Cover

October 2012
Volume 30 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tang, Z., Jiang, L., Peng, J., Ren, Z., Wei, D., Wu, C. ... Liu, L. (2012). PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. International Journal of Molecular Medicine, 30, 931-938. https://doi.org/10.3892/ijmm.2012.1072
MLA
Tang, Z., Jiang, L., Peng, J., Ren, Z., Wei, D., Wu, C., Pan, L., Jiang, Z., Liu, L."PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages". International Journal of Molecular Medicine 30.4 (2012): 931-938.
Chicago
Tang, Z., Jiang, L., Peng, J., Ren, Z., Wei, D., Wu, C., Pan, L., Jiang, Z., Liu, L."PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages". International Journal of Molecular Medicine 30, no. 4 (2012): 931-938. https://doi.org/10.3892/ijmm.2012.1072